N/A
Manufactured by Chartwell RX, LLC.
5,542 FDA adverse event reports analyzed
Last updated: 2026-04-15
BENZTROPINE MESYLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Chartwell RX, LLC.. The most commonly reported adverse reactions for BENZTROPINE MESYLATE include GRANULOCYTOPENIA, COMPLETED SUICIDE, TREMOR, DEATH, DIABETES MELLITUS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BENZTROPINE MESYLATE.
Out of 2,612 classified reports for BENZTROPINE MESYLATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 5,542 FDA FAERS reports that mention BENZTROPINE MESYLATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include GRANULOCYTOPENIA, COMPLETED SUICIDE, TREMOR, DEATH, DIABETES MELLITUS, DRUG INTERACTION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Chartwell RX, LLC. in connection with BENZTROPINE MESYLATE. Always verify the specific product and NDC with your pharmacist.